Wire Stories
EdiGene and Immunochina Announce Research and Development Collaboration to Develop Allogeneic CAR-T Therapy for Cancer
BEIJING, China & CAMBRIDGE, Mass.–(BUSINESS WIRE)–EdiGene, Inc., which develops genome editing technologies to accelerate drug discovery and develop novel therapeutics for a...